Breaking Finance News

A statement released today by FBR & Co. about Tesaro (NASDAQ:TSRO) raises the target price to $115.00

Stating a possible upside of 0.16%, FBR & Co. upped the price target of Tesaro (NASDAQ:TSRO) to $115.00

Previously on 9/6/2016, Lake Street released a statement on Tesaro (NASDAQ:TSRO) increased the target price from $0.00 to $114.00. At the time, this indicated a possible upside of 0.31%.

Just yesterday Tesaro (NASDAQ:TSRO) traded -0.63% lower at $99.26. Tesaro’s 50-day moving average is $96.42 and its 200-day moving average is $68.96. The last stock close price is up 43.94% relative to the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same time. 1,364,793 shares of TSRO traded hands, up from an average trading volume of 1,009,710

Performance Chart


With a market capitalization of $0, Tesaro has one year low of $29.51 and a one year high of $110.48 .

In addition to FBR & Co. reporting its target price, a total of 10 brokers have issued a research note on the company. The average target price is $89.00 with eight analysts rating the company a strong buy, 4 brokerages rating the stock a buy, 0 brokers rating the stock a hold, zero equity analysts rating the stock a underperform, and finally 0 analysts rating the company a sell.

Brief Synopsis On Tesaro (NASDAQ:TSRO)

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform. It offers VARUBI (rolapitant), which is an oral substance P/neurokinin 1 (NK-1) receptor antagonist for use in combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It is developing IV formulation of rolapitant, which has completed various Phase 1 clinical trials. Its niraparib is an orally active and poly (ADP-ribose) polymerase (PARP) inhibitor. Its immuno-oncology platform has immuno-oncology programs, which include TSR-022 and TSR-042.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *